WHO publishes a catalogue of tests to prioritize disease diagnosis
Category: #health  By Dhananjay Punekar  Date: 2018-05-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

WHO publishes a catalogue of tests to prioritize disease diagnosis

In what may seem to be quite a strategic move toward the improvisation of healthcare services across the globe, the World Health Organization has published its first ‘essential diagnostics list’. Fundamentally, this list is a catalogue of tests for detecting the most common conditions along with priority ailments.

Reportedly, this measure was taken to address problems in accessing diagnostic services, owing to which the masses have been unable to obtain proper treatment for ailments. For the record, nearly 46% of adults suffering from Type 2 diabetes across the globe were not diagnosed for diabetes. WHO has claimed that not detecting these disorders at the right time is likely to generate severe health problems and will also substantially raise healthcare costs.

It has been speculated that the late diagnosis of ailments such as TB and HIV raises the risk of their severity and makes it more difficult for the healthcare service providers to treat them accordingly. WHO also states that its essential diagnostics list focuses on in-vitro clinical tests such as Urine & blood tests for disease detection. In addition, fifty-eight tests included in the list are for identifying a large number of common disease conditions, generating a suitable platform for patient screening & handling activities. The rest of the fifty-five tests described in the list are used for diagnosing priority ailments such as Malaria, Syphilis, HIV, Hepatitis B, Hepatitis C, TB, and human papillomavirus.

Some of the clinical tests in the list are more suited for primary healthcare activities endowed with poor laboratory services. Experts claim that the list has been developed to serve as a guide for other nations through which they can create their own essential diagnostics lists.

According to some of WHO’s key officials, the list is likely to be upgraded regularly. In addition, WHO will also issue a call to various applications for appending new categories to the future editions.

The expansion of the list will continue in the future with the inclusion of antimicrobial resistance, new noncommunicable ailments, evolving pathogens, and ignored tropical diseases.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...